Investor/Share Issue 2025

Diagonal Bio carried out a rights issue of units in January/February 2025. In parallel, a directed issue to the same terms was conducted to trotting trainer Daniel Redén and Svea Bank AB. The motive for the transaction was to focus on validation of LAMPlify^®‘s commercial interest within the equine healthcare sector. The transaction was fully subscribed and provided Diagonal Bio with a total of approximately SEK 7.7 million before deduction of issue related costs and the issue proceeds are used for:

• Production of instruments and consumables
• Sales and marketing
• Intellectual property
• Working capital

Through the rights issue, warrants of series TO 2 were issued. The warrants have an exercise period in June 2025 and can provide the company with an additional SEK 3.6 million. Each warrant of series TO 2 gives the holder the right to subscribe for one new share in Diagonal Bio to the exercise price of SEK 0.01 per share.

It is the Board’s assessment that the net proceeds from the directed issue, the rights issue and fully exercised warrants of series TO 2 will fund the company’s operations until January 2026.